NEXALIN TECHNOLOGY INC
NXL · NASDAQ
Updated at 2026-10-13 15:23:11
- Today's High
- $3.37
- Today’s Low
- $2.62
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $3.63
- Previous Close
- $3.36
- Volume
- 75.16K
- Market Cap
- $2.78M
- P/E Ratio
- --
- EPS
- $-0.46
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Health Care
- Sub-industry
- MEDICAL DEVICES
- Headquarters
- 1776 YORKTOWN, HOUSTON, TX, UNITED STATES, 77056
- Country
- US
- Listing Date
- 2022-09-16
- Fiscal Year End
- December
- Shares Outstanding
- 22.01M
- CIK
- 0001527352
- Website
- nexalin.com
Nexalin Technology Inc. is a pioneering medical technology firm dedicated to transforming the treatment of neurological and psychiatric disorders through its proprietary transcranial electrical stimulation devices. By offering non-invasive solutions for prevalent mental health issues such as anxiety, depression, and substance addiction, the company underscores its commitment to improving patient outcomes and advancing accessible mental health care. With a robust research background and a strategic focus on tapping into the rising demand for innovative healthcare solutions, Nexalin is well-positioned for growth in the rapidly expanding digital health sector, presenting a compelling investment opportunity for institutional investors.
Financial Metrics
Revenue
2026-06-30
$12.16K
2026-03-31
$14.95K
2025-12-31
$171.89K
2025-09-30
$18.14K
Operating Expenses
2026-06-30
$2.25M
2026-03-31
$1.62M
2025-12-31
$2.56M
2025-09-30
$2.35M
Net Income
2026-06-30
-$2.23M
2026-03-31
-$2.09M
2025-12-31
-$2.37M
2025-09-30
-$2.27M
Net Profit Margin
2026-06-30
-18.41K%
2026-03-31
-14.02K%
2025-12-31
-1.38K%
2025-09-30
-12.54K%
Earnings Per Share
2026-06-30
$-0.11
2026-03-31
$-0.11
2025-12-31
$-0.13
2025-09-30
$-0.13
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$2.21M
2026-03-31
-$2.08M
2025-12-31
-$2.37M
2025-09-30
-$2.27M
Effective Tax Rate
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $12.16K | $14.95K | $171.89K | $18.14K |
| Operating Expenses | $2.25M | $1.62M | $2.56M | $2.35M |
| Net Income | -$2.23M | -$2.09M | -$2.37M | -$2.27M |
| Net Profit Margin | -18.41K% | -14.02K% | -1.38K% | -12.54K% |
| Earnings Per Share | $-0.11 | $-0.11 | $-0.13 | $-0.13 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$2.21M | -$2.08M | -$2.37M | -$2.27M |
| Effective Tax Rate | -- | -- | -- | -- |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.